Hi Donna - I too appreciate your sharing your story and agree with Paulo's hope the healthcare reform will bring outcomes based reimbursement. So much of the sound and fury in Washington is about...
Thanks for sharing Donna! Same old story of coverage decisions being made with a short term bias. Hoping that Healthcare reform will address some of this with outcomes based reimbursement. Take c...
biopharmaceutical research sector is strongly committed to advancing personalized medicine. A recent survey by theTufts Center for the Study of Drug Development found that 94% of our companies a...
The Age of Personalized Medicine Blog Experts discuss the latest science and policy issues in personalized medicine « For Cancer Therapies, It’s Getting Increasingly Personal
November, the Tufts Center for the Study of Drug Development reported that more than 90% of biopharmaceutical companies are investing in personalized medicine, with 12-50% of compounds in the dr...
in February this blog reported on the story of Adriana Jenkins, a breast cancer patient who, shortly before her death, called for policies to accelerate
https://ageofpersonalizedmedicine.wordpress.com/2011/02/16/adrianas-dying-wish/#comment-548
clinical effectiveness research. Regarding CER and personalized medicine, I’ll say now what I said late in late 2009: in the midst of the debate over health care reform — it remains to be ...
make sure the Board and Methodology Committee to integrate CER and PM. It seems to reinforce some concerns expressed earlier by PMC about lack of an expert in genomics or personalized medicine o...
The Age of Personalized Medicine Blog Experts discuss the latest science and policy issues in personalized medicine « Enabling Personalized Medicine Through Health Technology Innovations
The Age of Personalized Medicine Blog Experts discuss the latest science and policy issues in personalized medicine « The Role of Comparative Effectiveness Research in Total Cancer Care